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Hematopoietic cell transplantation (HCT)–specific comorbidity index: a new tool
for risk assessment before allogeneic HCT
Mohamed L. Sorror, Michael B. Maris, Rainer Storb, Frederic Baron, Brenda M. Sandmaier, David G. Maloney, and Barry Storer
We previously reported that the Charlson
Comorbidity Index (CCI) was useful for
predicting outcomes in patients undergo-
ing allogeneic hematopoietic cell trans-
plantation (HCT). However, the sample
size of patients with scores of 1 or more,
captured by the CCI, did not exceed 35%.
Further, some comorbidities were rarely
found among patients who underwent
HCT. Therefore, the current study was
designed to (1) better define previously
identified comorbidities using pretrans-
plant laboratory data, (2) investigate addi-
tional HCT-related comorbidities, and (3)
establish comorbidity scores that were
suited for HCT. Data were collected from
1055 patients, and then randomly divided
into training and validation sets. Weights
were assigned to individual comorbidi-
ties according to their prognostic signifi-
cance in Cox proportional hazard models.
The new index was then validated. The
new index proved to be more sensitive
than the CCI since it captured 62% of
patients with scores more than 0 com-
pared with 12%, respectively. Further, the
new index showed better survival predic-
tion than the CCI (likelihood ratio of 23.7
versus 7.1 and c statistics of 0.661 versus
0.561, respectively, P < .001). In conclu-
sion, the new simple index provided valid
and reliable scoring of pretransplant co-
morbidities that predicted nonrelapse
mortality and survival. This index will be
useful for clinical trials and patient coun-
seling before HCT. (Blood. 2005;106:
2912-2919)
© 2005 by The American Society of Hematology
Introduction
Comorbidity, as defined by Feinstein,1 is any distinct additional
clinical entity that has existed or may occur during the clinical
course of a patient with a primary (index) disease. Comorbidities
affect therapeutic plans and posttherapeutic outcomes of the index
disease.1 In patients with cancer as the index disease, multiple
studies have demonstrated the relevance of comorbidities in the
prognosis (reviewed in Extermann2). The number of comorbidities
was suggested to increase with aging of cancer patients (reviewed
in Extermann3). In Surveillance, Epidemiology, and End Results
(SEER) registry data, 75% of patients 55 years and older with colon
cancer had more than one comorbidity.4 However, patients with
comorbidities are often excluded from clinical trials, and there are
little data on how to translate results from cooperative studies to
patients with comorbid diseases. Therefore, the assessment of
comorbidities should be integrated into clinical trials, in addition to
functional status, particularly since comorbidities and functional
status can be used independently to predict outcomes.5-7 Efforts to
analyze the impact of comorbidities on index diseases are still in
their early stages. The interactions between the index diseases and
different comorbidities are variable based on the type and degree of
organ involvement. Therefore, several indices have introduced a
way to rate the impact of different comorbidities on the index
disease. One of these is the Charlson Comorbidity Index (CCI).
The CCI was developed by assigning weights for 19 chronic
conditions according to their association with 1-year mortality in a
cohort of 559 patients admitted to a general medical center. Then, a
summary score based on the sum of the weights was validated in a
cohort of breast cancer patients by evaluating the ability of scores
to predict mortality.8 Later, Charlson added age to her weighted
comorbidity scores by assigning an extra point for every decade of
age starting at 50 years.9 The CCI has been widely used in
predicting mortality risks in various medical conditions including
solid malignancies.3,10-17 We have recently used the CCI in the
settings of ablative and nonablative allogeneic hematopoietic cell
transplantation (HCT) for patients with hematologic malignancies.
In our studies, an adapted form of the CCI successfully predicted
the risks of nonrelapse mortality (NRM) in patients receiving
hematopoietic cell transplants from unrelated18 or related19 donors.
Those initial observations have been confirmed in several subse-
quent reports analyzing outcomes after nonmyeloablative HCT.20-23
However, some of the comorbidities described by Charlson were
rarely encountered in HCT patients due to existing exclusion
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criteria. This was particularly true for hepatic and pulmonary
comorbidities. In addition, the CCI did not capture some frequent
comorbidities, such as recent infections and psychiatric distur-
bances. Further, the CCI lacked sensitivity since comorbidities
were found in only 35% of patients, and this percentage was even
lower in patients undergoing ablative HCT (12% in unrelated18 and
22% in related19 ablative recipients). Some investigators have
pointed out the somewhat limited ability of the CCI to capture
comorbidities in patients with primary diagnoses other than
hematologic diseases.5,24 Others were successful in developing
disease-specific comorbidity indices by modifying the original CCI.12,13
With the development of nonmyeloablative HCT regimens and improve-
ments in the supportive care after myeloablative HCT regimens, more
patients with comorbidities are being offered allogeneic HCT.
Therefore, in the current study, we sought to identify those chronic
medical conditions, which were important in predicting NRM in
HCT patients, and then integrate these factors into a new scoring
system to assess survival probabilities after allogeneic HCT.
Patients, materials, and methods
The analysis was approved by the institutional review board of the Fred
Hutchinson Cancer Research Center (FHCRC, Seattle, WA). Informed
consent was provided according to the Declaration of Helsinki.
Patients: data source and patient selection
This analysis included consecutive and concurrent patients given either
nonablative (n 294) or ablative (n 761) conditioning followed by
hematopoietic cell grafts from related (1997-2003) or unrelated (2000-
2003) donors. Nonablative patients were conditioned with 2 Gy total body
irradiation (TBI) either alone (n 68) or preceded by fludarabine (n 226)
and were given postgrafting immunosuppression with cyclosporine (CSP)
and mycophenolate mofetil (MMF).25-28 Ablative patients were conditioned
with either busulphan/cyclophosphamide29 or cyclophosphamide/TBI30,31
and, in almost all cases, were given postgrafting immunosuppression with
CSP/methotrexate.32
Diagnoses and clinical grading of acute and chronic graft-versus-host
disease (GVHD) were performed using standard criteria.33,34 Primary
treatment of GVHD consisted of systemic corticosteroids, oral beclometha-
sone with or without systemic corticosteroids, or reinstitution of CSP.
Early detection of cytomegalovirus antigenemia and preemptive ganci-
clovir therapy were used for all patients35 as were standard prophylaxis
against Candida infections (fluconazole),36 bacterial infections (ceftazi-
dime or ciprofloxacin), Pneumocystis carinii infection (trimethoprim-
sulfamethoxazole or dapsone),37 and herpes simplex virus38 and varicella
zoster virus39 reactivation in serologically positive patients (acyclovir).
Low disease risk included acute leukemia in first complete remission,
chronic myeloid leukemia in first chronic phase, myelodysplasia-refractory
anemia, and nonmalignant hematologic diseases; while high disease risk
included all other diagnoses.
Data collection and modified comorbidities
Demographic data were obtained from the FHCRC database. Information
on comorbidities was extracted from detailed review of the patients’
medical charts and laboratory values at the time of HCT. All comorbidities,
which were encountered in the 1055 reviewed patients, were included in the
current study. Patients were given scores based on the original CCI.8 A new
HCT-specific comorbidity index (HCT-CI) was then developed as follows:
First, definitions of several comorbidities were modified as described in
Table 1. Second, comorbidities that were not found in the original CCI were
identified as newly investigated or additional comorbidities. Those included
bleeding, headache, osteoarthritis, osteoporosis, asthma, obesity, infection,
and psychiatric disturbances. The added comorbidities had to be active or
requiring treatment at the time of HCT, as defined by Charlson et al.8 Third,
all other comorbidities were assigned new weights in the HCT-CI using the
original definitions in the CCI,8 including gastrointestinal disease, coagu-
lopathy, endocrine disease, hypertension, arrhythmia, inflammatory bowel
disease, diabetes, cerebrovascular disease, rheumatologic disease, peptic
ulcer, and heart valve disease.
Assignment of new comorbidity weights
In order to develop the new HCT-CI, patients were randomly divided into 2
cohorts. Two thirds of the patients were assigned to a training set to develop
the scoring weights (n  708), and one third was assigned to a validation
set (n 347). Integer weights for the HCT-CI were derived from Cox
proportional hazards modeling applied to the training set, with NRM over
the first 2 years as the outcome. NRM was used instead of survival for
development of the scores, since deaths from nonrelapse causes are more
likely influenced by pretransplant comorbidities than deaths caused by
disease progression or relapse, which were treated as competing risks.
Adjusted hazard ratios (HRs) for NRM over the first 2 years after
transplantation were calculated for each comorbid condition, controlling for
the presence of all coexisting comorbidities as well as for age (younger
versus older than 50 years), type of conditioning (nonablative versus
ablative), and disease risk (high versus low). The adjusted HRs were
converted to integer weights according to the following: comorbidities with
adjusted HR of 1.2 or less were dropped from consideration, comorbidities
with adjusted HR of 1.3 to 2.0 were assigned a weight of 1, comorbidities
with adjusted HR of 2.1 to 3.0 were assigned a weight of 2, and
Table 1. Refinement of definitions of comorbidities
Comorbidity CCI definition New definition, from HCT-CI
Mild pulmonary Dyspnea on moderate activity Dyspnea on moderate activity or DLco and/or FEV1 81%-90%
Moderate pulmonary Dyspnea on slight activity Dyspnea on slight activity or DLco and/or FEV1 66%-80%
Severe pulmonary Dyspnea at rest or requires oxygen Dyspnea at rest or requires oxygen or DLco and/or FEV1 65%
Cardiac Congestive heart failure (symptomatic and requiring
treatment) and myocardial infarction were included
as independent comorbidities, each acquiring a
score of 1
Includes coronary artery disease,* congestive heart failure, myocardial infarction, or
ejection fraction 50%: one or more acquiring a score of 1
Mild hepatic Chronic hepatitis or cirrhosis Chronic hepatitis, bilirubin  ULN to 1.5 ULN, or AST/ALT ULN to 2.5 ULN
Moderate-severe hepatic Cirrhosis with portal hypertension  bleeding varices Cirrhosis, fibrosis, bilirubin 1.5 ULN, or AST/ALT2.5 ULN
Mild renal Serum creatinine 2-3 mg/dL Creatinine 1.2-2 mg/dL
Moderate-severe renal Creatinine 3 mg/dL, renal dialysis, or renal transplant Creatinine  2 mg/dL, renal dialysis, or renal transplant
Prior solid tumor Initially treated in the last 5 y Treated at any time point in the patient’s past history, excluding nonmelanoma skin
cancer
To convert creatinine from milligrams per deciliter to micromoles per liter, multiply milligrams per deciliter by 88.4.
*One or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft.
DLco indicates diffusion capacity of carbon monoxide; FEV1, forced expiratory volume in one second; ULN, upper limit of normal; AST, aspartate aminotransferase; and
ALT, alanine aminotransferase.
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comorbidities with adjusted HR of 3.1 or more were assigned a weight of 3.
The HCT-CI score was the sum of these integer weights. The HCT-CI
scores were further collapsed into 3 risk groups: 0 (low risk), 1 to 2
(intermediate risk), and 3 or more (high risk). For comparative purposes, the
original CCI was also reduced to 3 risk groups: 0, 1, and 2 or more.
Model validation
The scores of the new HCT-CI were applied to patients of the validation set
to test their ability to predict for HR and cumulative incidence of NRM. The
new HCT-CI was then compared with the original CCI for prediction of
both NRM and survival. Survival was added as an end point for comparison
between the 2 indices since the CCI scores were derived from Cox
proportional hazards modeling for survival.8 Cumulative incidence40 curves
for NRM and Kaplan-Meier curves for survival were computed for each
risk group defined by the 2 indices. Likelihood ratio statistics from
proportional hazards models were computed for both indices for events
over the first 2 years. Although a larger likelihood ratio statistic indicated a
better fit to the data, the likelihood ratio by itself had no intuitive
interpretation in terms of prediction. For this purpose, we also computed the
c-statistic.41 For a continuous predictor, the c-statistic could be interpreted
as the probability that a random pair of observations whose event times
could be ordered would have a concordant ordering of the predictor. A value
of 1.0 indicated perfect predictive discrimination, whereas a value of 0.5
indicated no ability to discriminate. If the data were collapsed to indicate a
binary outcome (survival larger or smaller than a fixed point in time), then
the c-statistic was also interpretable as the area under a receiver operating
characteristic curve. Pairs of observations whose ordering could not be
assigned because of censoring were excluded from the calculation. The
c-statistic was computed for NRM and survival, based on both time to event
over the first 2 years and as a binary outcome indicating event times
before/after 1 year or 2 years. For computing c-statistic for NRM, patients
were censored at the time of relapse/progression. Standard errors for the
c-statistic were estimated by applying a bootstrap procedure to the
validation dataset, using 100 bootstrap samples. Similarly, the standard
error for the difference in c-statistic between the CCI and HCT-CI was
estimated from the bootstrap samples and used to calculate a z-score and P
value for the difference.
Results
Patient characteristics
Characteristics of the 1055 patients included in this study are
shown in Table 2. A majority of patients received cyclophosphamide/
busulphan conditioning (43%), 29% received cyclophosphamide/
TBI (12-14.4 Gy), 22% received fludarabine/TBI (2 Gy), and 6%
received 2 Gy TBI. GVHD prophylaxis was MTX/CSP in 69% of
patients and MMF/CSP in 31%. Myeloid malignancies constituted
the majority of diagnoses (66%). Forty-one percent of the patients
had high risk disease. Median age was 44.8 years. Related grafts
were used in 58% of patients, while the remainder received
unrelated grafts. Thirteen percent of patients had preceding myeloa-
blative HCT, of which 2% were allogeneic, 6% were failed
autologous, and 5% were planned autologous. A majority of
patients received peripheral blood stem cell grafts (71%).
The HCT-CI
The prevalence of various comorbidities together with the cumula-
tive incidence and multivariate HR for 2-year NRM, as predicted
by each comorbidity, are shown in Table 3. The definitions of
comorbidities included in the HCT-CI, along with the integer
weights compared with those of the CCI, are shown in Table 4.
Pulmonary and hepatic abnormalities, as defined by laboratory
data, were the most frequent comorbidities in the new HCT-CI and,
together with prior solid tumor and heart valve disease, had the
highest assigned weights. By comparing conditions in the newly
derived HCT-CI with those of the CCI, a number of comorbidities
increased in relative importance, including arrhythmia, inflamma-
tory bowel disease, rheumatologic disease, peptic ulcer, moderate
and severe pulmonary comorbidity, prior solid tumor, and heart
valve disease. Other conditions, including cardiac disease, diabetes
mellitus, cerebrovascular disease, mild hepatic comorbidity, moder-
ate/severe renal comorbidity, and moderate/severe hepatic comor-
bidity, had comparable weights both in the HCT-CI and the original
CCI. Of the 8 comorbidities tested that were not specified by
Charlson, obesity, peritransplant infections, and psychiatric distur-
bances were assigned weights in the HCT-CI, whereas bleeding,
headache, osteoarthritis, osteoporosis, and asthma were not be-
cause of low predictive HR for NRM (0.0, 0.3, 0.4, 0.7, and 1.1,
Table 2. Patient and disease characteristics
Characteristic Data
Conditioning regimens, %
2 Gy TBI 6
Fludarabine 2 Gy TBI 22






















Median (range), y 44.8 (0.8-72.7)











TBI indicates total body irradiation; CY, cyclophosphamide; BU, busulfan; CSP,
cyclosporine; MMF, mycophenolate mofetil; MTX, methotrexate; AML, acute myeloid
leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndromes; ALL,
acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; MM, multiple myeloma;
CLL, chronic lymphocytic leukemia; HD, Hodgkin disease; HCT, hematopoietic cell
transplantation; and G-PBMC, granulocyte colony stimulating factor-mobilized periph-
eral blood mononuclear cells.
*Immunodeficiency syndrome, chronic granulomatous disease, congenital dyser-
ythropoietic anemia, paroxysmal nocturnal hemoglobinuria, polycythemia vera,
thalassemic syndrome, and sickle cell anemia.
†Low indicates acute leukemia in first remission, CML in first chronic phase,
MDS-refractory anemia, or nonmalignant hematologic disease; while high indicates
all other diagnoses.
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respectively). For peripheral vascular disease, no conclusions could
be drawn since none of the current patients had this comorbidity at
the time of HCT.
The HCT-CI scores ranged from 0 to 11 in the training set,
compared with 0 to 4 for the original CCI scores.
Validation of the new HCT-CI
The newly developed HCT-CI scores were then calculated for
patients in the independent validation set (n  347). The HR
and 2-year cumulative incidence of NRM are summarized by
HCT-CI scores for the training and validation sets in Table 5.
Due to small numbers, patients with scores of 4 or more were
collapsed into one group. Probably due to the smaller number of
patients, there was an apparent shrinkage of the discriminatory
ability for NRM among various risk groups between the training
and validation sets; nevertheless, the HCT-CI continued to be
strongly associated with NRM.
Comparing the new HCT-CI with the original CCI
For the purpose of comparison, the 2 comorbidity indices were
each separated into 3 risk groups. For the HCT-CI these were low
(0), intermediate (1-2), and high ( 3) and for the CCI, low (0),
intermediate (1), and high ( 2). Results for NRM and survival are
summarized by risk group in Table 6 and Figure 1. It was clear that
the risk groups based on the HCT-CI scores were more evenly
distributed and provided better discrimination of NRM risks than
the risk groups defined by the CCI. Although the risk groups for
both indices provided some discrimination for survival, the CCI
had a lower overall predictive value for survival because of the
concentration of nearly 90% of scores in the 0 score category.
Statistical comparisons between the HCT-CI and CCI are
summarized in Table 7. There was stronger association of higher
HCT-CI scores with worse NRM and survival based on the
likelihood ratio. In addition, the c-statistics were significantly
higher using the HCT-CI compared with the CCI, whether as an
overall measure of association (the percent of pairs of patients
where the patient with the higher comorbidity score failed first) or
for association with a dichotomized end point at 1 year or 2 years
(the percent of pairs of patients where the patient failing before 1
year or 2 years had a higher comorbidity score than the patient
failing after that time).
Correlation between causes of death and most
common comorbidities
Pulmonary comorbidities, as defined by impairments of forced
expiratory volume in one second (FEV1) and/or diffusion capacity
of carbon monoxide (DLco), and hepatic comorbidities, as defined
by elevations of hepatic function tests, were the most prevalent
comorbidities captured by the new HCT-CI. There were 347
patients with moderate (score 2) or severe (score 3) pulmonary
comorbidities, and 122 died from nonrelapse causes. Causes of
NRM among these 122 patients included pulmonary toxicities
(24%), GVHD (11%), and infections (45%) with (18%) or without
(27%) GVHD (infections involved the lungs in almost half of the
cases), and 20% died from other causes.
Mild (score 1) and moderate-severe (score 3) hepatic comorbidi-
ties were encountered in 215 patients, of whom 72 died of
nonrelapse causes. Twenty-one percent of these 72 patients died
from GVHD; 10%, from hepatic causes; 36%, from infections with
or without GVHD; 15%, from pulmonary causes; and 18%, from
other causes.
Overall, fewer nonablative than ablative patients had scores of 0
(29% versus 41%) and 1 to 2 (31% versus 35%), while more nonablative
than ablative patients had scores of 3 or more (40% versus 24%).
Discussion
We previously reported on the importance of pretransplant comor-
bidities for outcomes after allogeneic HCT18,19 using the CCI, given
that it was a validated and simple scoring system for comorbidities.
The studies were confined both by small sample sizes and the
limited ability of the CCI to comprehensively capture comorbidities,
particularly in patients given ablative conditioning. The current study
refined comorbidity definitions, added newly identified comorbidi-
ties, and evaluated each comorbidity category by Cox regression
hazard models. A new index of scores for each comorbidity was
then developed and validated in another randomly selected group
of HCT recipients. We found that the HCT-CI captured more
pretransplant comorbidities and provided better assessment of
NRM and survival risks compared with the original CCI.
The adverse impact of comorbidities on cancer patients was
likely due to the physiologic burden of chronic disease and its
interactions with cancer and cancer treatment.42 Therefore, in-
creased severity of comorbidities increased the risk of toxicities in
response to specific treatments and, hence, shortened life expect-
ancy and canceled gains derived from specific therapies.43 There
has been ample evidence in the literature that comorbidities and
Table 3. Prevalence of comorbidities among 708 patients included
in the training set with cumulative incidences and multivariate HRs
of comorbidities for 2-year NRM
Comorbidity Prevalence, % 2-year NRM, % Multivariate HR*
Bleeding† 1 0 0.0
Headache† 4 8 0.3
Osteoarthritis† 1 11 0.4
Gastrointestinal disease 9 20 0.5
Coagulopathy 6 30 0.6
Osteoporosis† 1 75 0.7
Renal, mild‡ 10 24 0.8
Endocrine disease 5 31 1.0
Asthma† 2 14 1.1
Pulmonary, mild‡ 16 18 1.1
Hypertension 10 33 1.2
Arrhythmia 5 35 1.3
Cardiac‡ 5 37 1.3
Inflammatory bowel disease 1 31 1.3
Diabetes 3 50 1.6
Cerebrovascular disease  1 67 1.6
Psychiatric disturbance† 9 29 1.8
Hepatic, mild‡ 16 30 1.9
Obesity† 2 33 1.9
Infection† 4 40 1.9
Rheumatologic 4 45 2.3
Peptic ulcer 1 38 2.5
Renal, moderate/severe‡ 2 42 2.6
Pulmonary, moderate‡ 24 36 3.0
Prior solid tumor‡ 2 38 3.1
Heart valve disease 2 33 3.3
Pulmonary, severe‡ 9 39 3.7
Hepatic, moderate/severe‡ 4 43 3.9
Peripheral vascular disease 0 — —
— indicates not applicable.
*Adjusted for all other comorbidities, age, high disease risk, and conditioning
type.
†Newly investigated comorbidities.
‡Comorbidities with modified definitions compared with the original CCI.
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performance scales both independently predicted for outcome.5
However, contrary to functional status, comorbidities presented the
unique challenge of being a multidimensional variable, since
diseases influencing mortality might not be the same as diseases
influencing function or tolerance to treatment.2 Translating comor-
bidities into weighted scores appeared to be the best way to use
comorbidities for prediction of outcome.2,8,44,45
In the current study, we sought to modify the CCI in a way to
improve sensitivity and specificity for predicting risks of NRM
after HCT. The primary modification was refinement of several
comorbidity definitions, which was done by introducing objective
laboratory and functional testing data, thereby incorporating sub-
clinical organ impairments that could result in partial compromise
in patients subjected to the intensive physiologic challenge of HCT.
Pulmonary function tests were used to define different grades of
pulmonary comorbidities. Similarly, liver function tests and cardiac
ejection fraction were added to definitions of hepatic and cardiac
comorbidities. This introduction of laboratory data constituted the
main change for increasing the sensitivity of the new HCT-CI, in
particular since pulmonary and hepatic comorbidities achieved the
highest prevalence among our transplant populations. The new
HCT-CI captured 62% of patients with scores more than 0
compared with 12% captured by the original CCI. In particular,
59% of ablative patients had scores more than 0 using the HCT-CI
compared with 10% by the original CCI.
The improvement in the new HCT-CI over the original CCI was
demonstrated by likelihood ratio and c statistics. The improvement
was likely related to the assignment of comorbidity weights
specific to patients who underwent transplantation. Several com-
mon comorbidities were assigned higher weights than in the
original CCI, likely reflecting their importance for tolerating HCT.
In addition, new comorbidities, such as infections, obesity, and
psychiatric disturbances, were found to be clinically relevant. The
use of laboratory data in the new HCT-CI accounted for larger
numbers of patients with scored comorbidities, which added to the
utility of the new HCT-CI over the original CCI.
In all cases, the c-statistic calculated for the HCT-CI was 7 to 15
percentage points higher than that for the CCI, with the value for
the CCI being only slightly better than a coin flip (0.50). Although
the difference between HCT-CI and CCI was highly statistically
significant, it should be noted that the magnitude of the c-statistic for the
HCT-CI reflected a fairly modest level of prediction. This was not
Table 4. Definitions of comorbidities included in the HCT-CI and HCT-CI scores compared with original CCI scores
Comorbidity Definitions of comorbidities included in the new HCT-CI HCT-CI weighted scores Original CCI scores*
Arrhythmia Atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias 1 0
Cardiac‡ Coronary artery disease,§ congestive heart failure, myocardial infarction,
or EF 50%
1 1
Inflammatory bowel disease Crohn disease or ulcerative colitis 1 0
Diabetes Requiring treatment with insulin or oral hypoglycemics but not diet alone 1 1
Cerebrovascular disease Transient ischemic attack or cerebrovascular accident 1 1
Psychiatric disturbance† Depression or anxiety requiring psychiatric consult or treatment 1 Not included
Hepatic, mild‡ Chronic hepatitis, bilirubin ULN to 1.5 ULN, or AST/ALT ULN to
2.5 ULN
1 1
Obesity† Patients with a body mass index 35 kg/m2 1 Not included
Infection† Requiring continuation of antimicrobial treatment after day 0 1 Not included
Rheumatologic SLE, RA, polymyositis, mixed CTD, or polymyalgia rheumatica 2 1
Peptic ulcer Requiring treatment 2 1
Moderate/severe renal‡ Serum creatinine 2 mg/dL, on dialysis, or prior renal transplantation 2 2
Moderate pulmonary‡ DLco and/or FEV1 66%-80% or dyspnea on slight activity 2 1
Prior solid tumor‡ Treated at any time point in the patient’s past history, excluding
nonmelanoma skin cancer
3 2
Heart valve disease Except mitral valve prolapse 3 0
Severe pulmonary‡ DLco and/or FEV1 65% or dyspnea at rest or requiring oxygen 3 1
Moderate/severe hepatic‡ Liver cirrhosis, bilirubin  1.5 ULN, or AST/ALT 2.5 ULN 3 3
To convert creatinine from milligrams per deciliter to micromoles per liter, multiply milligrams per deciliter by 88.4.
EF indicates ejection fraction; ULN, upper limit of normal; SLE, systemic lupus erythmatosis; RA, rheumatoid arthritis; CTD, connective tissue disease; DLco, diffusion
capacity of carbon monoxide.
*Definitions of comorbidities included in the original CCI are defined in the appendix of a prior publication.8
†Newly investigated comorbidities.
‡Comorbidities with modified definitions compared with the original CCI.
§One or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft.
Table 5. The new HCT-CI scores and prediction for NRM and survival the training versus the validation set
Score





HR* (95% CI) 2-year, % HR* (95% CI) 2-year, %
0 38 1 9 38 1 14
1 17 1.66 (0.9-3.1) 14 18 1.57 (0.7-3.3) 22
2 17 3.48 (2.0-6.0) 27 17 1.26 (0.6-2.8) 19
3 17 6.09 (3.7-10.1) 41 15 3.95 (2.1-7.5) 41
4 or more 11 6.93 (4.0-12.0) 43 13 3.05 (1.5-6..2) 40
For the training set, n 708; for the validation set, n 346.
*Adjusted for age, disease risk, and conditioning.
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surprising given the multiple factors that also contributed to both NRM
and survival and the smaller patient sample in the validation set.
Even though the HCT-CI scores were highly effective in
predicting outcome of patients after HCT, other major pretransplant
factors played significant roles. Age and disease stage of a specific
hematologic malignancy were additional factors that should be
considered when determining HCT risks. Age has been used
independently to determine if patients should be referred for HCT
and to stratify patients for the different intensity conditioning
regimens.46-49 For that reason and also since age is a demographic
variable, we decided not to include age as a scored comorbidity in
the HCT-CI. Instead, in the current study, age was used to adjust the
Cox regression hazards’ modeling for developing the new HCT-CI.
We and other investigators had shown the importance of single
organ comorbidities and abnormal laboratory data, as markers of
organ dysfunction, on outcome of patients who underwent transplan-
tation.50-52 However, none have attempted to evaluate multiple
comorbidities into a scoring system with predictive power to
determine survival risks after HCT. On the other hand, some
disease-specific prognostic scoring systems53,54 have been devel-
oped for assessing patient risk prior to specific therapies including
HCT. However, none of those scores took into account the impact
of different comorbidities on outcome.
There were several limitations to our study. The first was the
retrospective nature of the data collection. Since we relied on data
recorded in medical charts, some potentially important data might
not have been recorded and hence not been included in this
analysis. However, the introduction of laboratory and functional
data, most of which were stored in the database, has likely reduced
the possibility of missing comorbidities. To better address this
problem, new protocols include prospective scoring of enrolled
patients. The second limitation was that patients from the same
institution were used to validate the new HCT-CI. Efforts are under
way to further validate the HCT-CI on patients who underwent
transplantation in other institutions. The third limitation was the
lack of interrater and test-retest reliabilities in this study. However,
reports on the original CCI had previously shown both good
interrater reliability between 0.74 and 0.945 by interclass correla-
tion coefficient in older cancer patients5,55 and good test-retest
reliability of 0.92.56 Since we used many of the definitions of the
CCI with additional refinements based on laboratory and functional
testing, which were not subject to investigator variations, it was
likely that the HCT-CI had at least the same interrater reliability as
the original CCI. We plan to test the HCT-CI reliability among
different investigators located in different institutions.
The current HCT-CI could be applied to a number of settings.
Our study identified prevalent and prognostically important
coexisting illnesses that should be measured and considered in
clinical trials and HCT registries. This would help to extrapolate
the results of transplant recipients with significant comorbidities
to the entire spectrum of HCT patients. A second application of
this HCT-CI involves the consideration of medical evidence for
individual patients at the bedside. The index can be widely used
by referring physicians, oncologists, and hematologists when
assessing the risks of patients with hematologic diseases for
specific therapies and particularly referral for HCT. Currently,
we investigate the importance of the new HCT-CI on outcomes in
disease-specific patients given HCT. The third application includes
a wide area of research concerning the correlation between
comorbidities captured by the HCT-CI and different complications
after HCT, such as infections, GVHD, and respiratory or hepatic
Figure 1. The HCT-CI compared with the CCI. Cumulative incidences of nonre-
lapse mortality (NRM) as stratified by the (A) new HCT-CI compared with (B) the
original CCI, and Kaplan-Meier estimates of survival as stratified by (C) the new
HCT-CI compared with (D) the original CCI among patients of the validation set. Only
13% of patients had scores of 1 or more when scored by the original CCI compared
with 62% when scored by the new HCT-CI.











% HR* (95% CI)
2-year,
% HR* (95% CI)
2-year,
% HR* (95% CI)
2-year,
%
0 38 1.0 14 1.0 71 0 87 1.0 23 1.0 59
1 to 2 34 1.42 (0.8-2.7) 21 1.31 (0.8-2.0) 60 1 10 1.25 (0.6-2.5) 29 1.32 (0.8-2.2) 49
3 or more 28 3.54 (2.0-6.3) 41 2.69 (1.8-4.1) 34  2 3 1.46 (0.5-4.7) 25 2.78 (1.4-5.6) 17
*Adjusted for age, disease risk, and conditioning.
Table 7. Comparisons between the HCT-CI and the CCI in the




3 risk groups P *
Nonrelapse mortality
c-statistic (SE*), overall 0.649 (0.029) 0.520 (0.019)  .001
c-statistic (SE*), yes/no 2 y 0.685 (0.037) 0.532 (0.023)  .001
c-statistic (SE*), yes/no 1 y 0.692 (0.036) 0.546 (0.025)  .001
Likelihood ratio 26.6 1.2
Adjusted likelihood ratio† 21.4 0.7
Overall survival
c-statistic (SE*), overall 0.624 (0.021) 0.536 (0.015)  .001
c-statistic (SE*), yes/no 2 y 0.657 (0.031) 0.548 (0.019)  .001
c-statistic (SE*), yes/no 1 y 0.661 (0.030) 0.561 (0.021)  .001
Likelihood ratio 31.8 7.6
Adjusted likelihood ratio† 23.7 7.1
*Estimated from 100 bootstrap samples
†Adjusted for age, disease risk, and conditioning.
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failure. The final application will be stratifying patients for
eligibility of nonablative versus ablative HCT.
In summary, we have developed a new tool for capturing
pretransplant comorbidities that could be used in predicting
outcomes and stratifying patients for HCT. In the future, we will
further validate this index on patients from different institutions
and compare its performance to comorbidity indices other than the
CCI, such as The Cumulative Illness Rating Scale and the Adult
Comorbidity Evaluation (ACE-27). Further, it would be of interest
to develop a scaling system for increments of age and different
stages of diseases to be used in concert with the HCT-CI in assessing
pretransplant patient risk for failure of disease-free survival.
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